WEISS MICHAEL S

Average Profitability
76.33%
Insider Buys Quantity
9
Insider Buys Sum
$6.22M
Insider Sells Quantity
3
Insider Sells Sum
$4.75M

Insider Activity of WEISS MICHAEL S

According to the SEC Form 4 filings, WEISS MICHAEL S, being in a position of

  1. See Remarks at Fortress Biotech, Inc.,
    оver the last 12 months, has bought 147058 shares for $249,999, and sold 0 shares,
    over all time since 2014-11-06, has bought 3344662 shares for $4.47M, and sold 0 shares.

The largest purchase of all time was on 2014-11-06 and amounted to 2000000 shares of Fortress Biotech, Inc. for $3.22M.

The largest sale of all time was on 2014-12-16 and amounted to 210618 shares of TG Therapeutics, Inc. for $3.46M.

Biography of WEISS MICHAEL S

No biography is available at this moment.

2023-11-14PurchaseFortress Biotech, Inc.
FBIO
See Remarks
147,058
0.1391%
$1.70$249,999+46.15%
2023-08-11PurchaseTG Therapeutics, Inc.
TGTX
CEO and President
100,000
0.0669%
$10.13$1.01M+49.16%
2023-02-10PurchaseFortress Biotech, Inc.
FBIO
See Remarks
1.2M
1.2914%
$0.83$999,999-35.51%
2022-01-05SaleTG Therapeutics, Inc.
TGTX
CEO and President
30,671
0.0239%
$18.31$561,586-57.97%
2022-01-04SaleTG Therapeutics, Inc.
TGTX
CEO and President
37,549
0.0281%
$19.20$720,941-61.45%
2019-06-26PurchaseTG Therapeutics, Inc.
TGTX
CEO and President
50,000
0.0581%
$7.04$351,750+34.6%
2014-12-16SaleTG Therapeutics, Inc.
TGTX
See Remarks
210,618
0.6057%
$16.44$3.46M-9.77%
2014-11-06PurchaseFortress Biotech, Inc.
FBIO
Exec. VC - Strategic Dev.
2M
5.3546%
$1.61$3.22M+82.3%
2013-12-11PurchaseTG Therapeutics, Inc.
TGTX
See Remarks
10,000
0.0337%
$3.43$34,300+118.06%
2012-09-11PurchaseTG Therapeutics, Inc.
TGTX
See Remarks
100,000
0.6325%
$2.25$225,000+140%
2012-09-10PurchaseTG Therapeutics, Inc.
TGTX
See Remarks
50,000
0.3162%
$2.25$112,500+137.78%
2012-05-16PurchaseTG Therapeutics, Inc.
TGTX
See Remarks
1,500
0.0128%
$6.25$9,375-39.52%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.